The MHT Decision Is a Cardiac Decision. Here Is What a Cardiologist Considers.

In July 2002, the Women’s Health Initiative published results from its combined hormone therapy arm. The headline: hormone therapy increases heart disease risk in women. Within months, 20 million women stopped their prescriptions. Their physicians told them to stop. The medical culture shifted, largely and quickly, toward treating menopausal symptoms without hormones.

Twenty years later, the scientists who ran that study said: we should have been clearer about who should and should not take it. The study enrolled women with a mean age of 63, many of whom already had subclinical cardiovascular disease. The results applied to that population. They were applied, wholesale, to perimenopausal women in their 50s. That was the error.

Most women never received the correction.

What the WHI actually showed

The WHI enrolled 16,608 women aged 50 to 79. Mean age: 63. This is not the perimenopausal population for whom MHT is primarily relevant. It is a population of older postmenopausal women, many years past their last menstrual period, a substantial proportion of whom had subclinical coronary artery disease at the time they received hormones. 5 / Solid

The combined arm used conjugated equine estrogen plus medroxyprogesterone acetate (MPA), in oral form. It showed a modest increase in coronary events (37 per 10,000 women per year vs. 30 in the placebo group) and an increase in breast cancer (38 per 10,000 vs. 30 in placebo).

The estrogen-only arm (post-hysterectomy women, no progestogen) showed no increased coronary events. It showed no increased breast cancer. It showed a possible reduction in breast cancer. 5 / Solid

These are different results. They were reported as one headline.

The timing hypothesis: what the re-analyses showed

The timing hypothesis emerged from observational data and was confirmed by multiple intervention trials and WHI sub-analyses. The central finding: age and time since menopause at the time of MHT initiation determines whether cardiovascular risk is increased or potentially decreased. 5 / Solid

When WHI data was re-analyzed by age group:

Women aged 50-59 at enrollment showed a non-significant reduction in coronary events. The cardiovascular signal in this younger group was favorable or neutral.

Women aged 60-69 showed a small increase. Women aged 70-79 showed a clearer increase.

The pattern: the earlier in the menopause transition that MHT is started, the more favorable the cardiovascular profile.

Supporting trials:

The ELITE trial (Early vs. Late Intervention Trial with Estradiol) randomized women to estradiol within 6 years of menopause vs. more than 10 years after menopause. The early-initiation group showed significantly slower progression of carotid intima-media thickness (a structural marker of subclinical atherosclerosis). The late-initiation group did not. This was the closest thing to a randomized test of the timing hypothesis. 5 / Solid

The DOPS trial (Danish Osteoporosis Prevention Study) randomized recently postmenopausal women to MHT or no MHT and followed them for 10 years. The MHT group showed significantly lower rates of cardiovascular death, MI, and heart failure. 4 / Promising

The KEEPS trial found no change in atherosclerosis progression in recently menopausal women on low-dose estrogen, consistent with a neutral effect in women without established subclinical disease. 4 / Promising

The current scientific consensus, endorsed by the Menopause Society, the British Menopause Society, and European menopause societies: for healthy women under 60 or within 10 years of menopause, without established cardiovascular disease, the cardiovascular risk of MHT is low and the benefit-risk balance is generally favorable.

Transdermal vs. oral estrogen: a difference that matters clinically

This is not a minor formulation detail. It changes the cardiovascular and clot risk profile meaningfully.

Oral estrogen undergoes first-pass hepatic metabolism. The liver, receiving a concentrated bolus of estrogen, responds by producing more clotting factors (particularly factor VII and fibrinogen), raising triglycerides, and increasing inflammatory proteins including CRP. The result: measurably increased VTE risk and possibly increased arterial inflammatory burden. 5 / Solid

Transdermal estrogen (patch, gel, spray) delivers estrogen directly into the systemic circulation, bypassing the liver. The hepatic first-pass effect does not occur. Transdermal estrogen does not meaningfully increase VTE risk in population studies. It has neutral or favorable effects on triglycerides. For women with cardiovascular risk factors, migraine with aura, or prior clot history, transdermal is the preferred route. 5 / Solid

The WHI used oral estrogen. The trials that showed elevated clot risk were largely or entirely oral estrogen trials. This context was frequently lost in the translation of “hormone therapy increases clot risk” to clinical practice, the statement is accurate for oral estrogen and not established for transdermal.

The progestogen question

Women with an intact uterus require a progestogen alongside estrogen to protect the endometrium. The choice of progestogen matters for cardiovascular profile.

Micronized progesterone (Prometrium, Utrogestan) is bioidentical progesterone, the same molecular structure as the body’s own hormone. It does not oppose estrogen’s HDL-raising effects, has less adverse impact on inflammatory markers, and carries less adverse thrombogenic signal than synthetic progestins. Observational studies suggest it has a better breast cancer profile than synthetic progestins (though this is not yet proven in randomized trials). 4 / Promising

Synthetic progestins (medroxyprogesterone acetate, norethisterone, levonorgestrel) have been more extensively studied but carry less favorable metabolic profiles. MPA, used in the WHI combined arm , opposes some of estrogen’s beneficial vascular effects and worsens the lipid profile compared to micronized progesterone.

The Menopause Society 2022 position statement and the British Menopause Society guidance both identify micronized progesterone as the preferred progestogen for women who need combined therapy, based on currently available evidence.

What a complete MHT discussion covers

Before initiating MHT, the following should be addressed:

Time since menopause. The timing window is within 10 years of last menstrual period or before age 60 for healthy women. Outside this window, initiation in women with cardiovascular risk factors requires a more individualized benefit-risk conversation.

Baseline cardiovascular risk assessment. Blood pressure, lipids, fasting insulin, hs-CRP. A woman with well-controlled cardiovascular risk factors and no established CVD is a different MHT candidate than a woman with uncontrolled hypertension and elevated inflammatory markers.

Formulation route. Transdermal estradiol preferred for women with any cardiovascular risk factors, migraine with aura, elevated triglycerides, or clot history.

Progestogen selection. Micronized progesterone preferred for women with intact uterus, unless there is a specific clinical reason to use a different agent.

Duration. There is no evidence-based duration limit for women who remain symptomatic and who have appropriate baseline risk. The “5-year rule” that circulates in primary care is not supported by current guidelines. For women started at the appropriate time with appropriate formulations and risk factors controlled, duration is driven by ongoing benefit-risk assessment rather than arbitrary time cutoff.

Contraindications to review. Prior hormone-receptor-positive breast cancer (not all breast cancer), prior unprovoked VTE, unexplained vaginal bleeding, active liver disease, recent cardiovascular event.

The conversation to have with your physicians

The MHT decision optimally involves both the prescribing clinician (gynecologist, internist, or menopause specialist) and someone who can evaluate the cardiovascular picture. These conversations do not always happen at the same time or in the same office.

If you are considering MHT and have any of the following, ask specifically for a cardiologist’s input:

• Personal history of coronary artery disease, prior MI, or stroke
• History of SCAD
• Prior VTE (blood clot)
• Significant family history of premature cardiovascular disease
• Uncontrolled hypertension or complex lipid picture

Questions to ask your prescribing clinician:

“Based on the timing hypothesis evidence, am I within the window where MHT cardiovascular risk is low?”

“Given my cardiovascular risk factors, should we be using transdermal rather than oral estrogen?”

“Is micronized progesterone the right progestogen choice for me given the cardiovascular profile evidence?”

The symptom case for MHT: what it is actually for

MHT is a treatment for menopausal symptoms. That sentence is the anchor for everything that follows in this article. The cardiovascular risk conversation exists to inform a symptom-treatment decision — not to establish MHT as a cardiac therapy, and not to scare women away from a treatment they may genuinely need.

The symptoms that MHT treats are not trivial. Vasomotor symptoms — hot flashes and night sweats — affect approximately 75 to 80% of women going through the menopausal transition. In 25 to 30% of those women, the severity is sufficient to significantly disrupt daily function and sleep quality: multiple nocturnal awakenings, daytime fatigue, difficulty concentrating, and impaired performance at work. 5 / Solid

These symptoms do not resolve quickly in most women. Data from the Study of Women’s Health Across the Nation (SWAN) and more recent longitudinal cohorts suggest that vasomotor symptoms can persist 7 to 10 or more years after the final menstrual period for a substantial proportion of women — not months, years. Women in the severe-symptom group frequently have the longest symptom duration.

Beyond vasomotor symptoms, MHT addresses genitourinary syndrome of menopause (GSM): vaginal dryness, dyspareunia (pain with intercourse), and urinary symptoms including urgency and recurrent urinary tract infections. GSM affects approximately half of postmenopausal women and does not resolve without treatment — it progressively worsens. Local or systemic estrogen is the primary effective intervention. 5 / Solid

Mood destabilization during the perimenopause transition — not simply “feeling sad,” but the neurological volatility that accompanies rapidly fluctuating estrogen — is a third domain where MHT provides documented benefit in appropriately selected women.

For moderate-to-severe vasomotor symptoms specifically, no non-hormonal therapy approaches the efficacy of MHT in head-to-head trials. Non-hormonal options including SSRIs, SNRIs, gabapentin, oxybutynin, and the newer NK3 receptor antagonists (fezolinetant) reduce hot flash frequency meaningfully, but the magnitude of symptom reduction in comparison trials consistently shows MHT’s superior efficacy for women with severe symptoms.

This context reshapes the cardiovascular risk conversation. The cardiovascular assessment surrounding MHT is a safety evaluation for a treatment that has documented, substantial symptom management benefit. Women who decline MHT based on cardiovascular fear alone — without undergoing an individualized risk assessment — may be choosing years of disrupted sleep, reduced quality of life, and the secondary cardiovascular effects of chronic sleep deprivation (itself an established cardiovascular risk factor) over a treatment that, properly evaluated, may carry fully acceptable risk.

The decision is about symptoms. The cardiovascular conversation ensures the decision is made with accurate risk data, not with an outdated 2002 headline.

Monitoring and ongoing assessment while on MHT

Starting MHT is the beginning of an active clinical relationship with the medication, not a one-time prescription event. The monitoring framework mirrors what any thoughtfully managed cardiovascular medication requires: baseline data, early-course checks, and systematic annual review.

Blood pressure should be checked within 3 months of starting MHT and then at minimum annually thereafter. Oral estrogen can occasionally raise blood pressure through aldosterone-mediated pathways — the hepatic first-pass effect that oral estrogen triggers includes effects on renin-angiotensin-aldosterone signaling that transdermal estrogen does not. 4 / Promising If blood pressure rises meaningfully after starting oral estrogen, the appropriate first step is to consider a route change to transdermal before adding antihypertensive medication. Route change is a simpler, mechanism-targeted intervention.

Lipid panel at baseline before MHT initiation provides the reference point. For women with baseline cardiovascular risk factors, annual lipid surveillance is appropriate. Transdermal estradiol typically produces modest LDL reduction and HDL elevation without the triglyceride elevation that oral estrogen can cause. Oral estrogen often has a more pronounced favorable effect on total cholesterol and LDL, but raises triglycerides — a relevant consideration for women with baseline hypertriglyceridemia or metabolic syndrome. 5 / Solid

Breast surveillance follows standard population guidelines regardless of MHT use; annual mammography remains the backbone of this surveillance. Women on MHT, particularly combined estrogen-progestogen therapy, may experience increased breast density over time, which can affect mammogram sensitivity. Radiologists should be informed of current MHT use. If density increases significantly, supplemental imaging (tomosynthesis or ultrasound) may be appropriate to discuss with the ordering clinician.

The 5-year risk-benefit review is the standard of care recommendation from the Menopause Society and British Menopause Society. At 5 years of continuous MHT use, the prescribing clinician should formally document a reassessment: are symptoms still present and still benefiting from treatment, has the risk profile changed, are formulation adjustments indicated? This is not a duration cap — there is no evidence-based maximum duration for women who remain symptomatic and whose risk factors are well-controlled. The “stop at 5 years” instruction that circulates in primary care conflates a review recommendation with a discontinuation mandate. The two are different. 5 / Solid

If a cardiovascular event occurs during MHT — myocardial infarction, stroke, or venous thromboembolism — MHT should be paused promptly, and formal cardiovascular review should be initiated before any decision about resumption. This is not an automatic permanent discontinuation order; it is an indication for expert reassessment. Women with underlying heart disease who were appropriately started on MHT and have been clinically stable are not automatically required to stop on the basis of their diagnosis alone. But ongoing management in that context requires a cardiologist familiar with the MHT evidence base, not a reflexive discontinuation driven by the 2002 headlines.

The monitoring frame is this: MHT is an active medication decision that requires the same surveillance discipline as antihypertensive or statin therapy. Initiation without a plan for follow-up is incomplete clinical management.

Related reading

For the full hormonal cardiovascular picture: Estrogen Is Not Just a Reproductive Hormone.

For the cardiovascular changes that accelerate in the perimenopause transition: Your Doctor Said You Are Safe Until Menopause.

For a SCAD survivor considering MHT specifically: SCAD: The Heart Attack That Tears the Artery Wall.